Authors
Latest:
Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?In this review, we will discuss the role of geriatric assessment, alternative treatment modalities for older women with triple-negative breast cancer, and other special considerations for this patient population.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.
Latest:
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future TrialsIn Part 2 of this two-part series, we review the clinical evidence in support of combining immunotherapy with stereotactic radiosurgery for the treatment of brain metastases; examine controversies regarding radiation dose and fractionation, as well as temporal sequencing of multimodality treatment; and discuss future directions in combined therapy.
Latest:
Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future TrialsIn Part 2 of this two-part series, we review the clinical evidence in support of combining immunotherapy with stereotactic radiosurgery for the treatment of brain metastases; examine controversies regarding radiation dose and fractionation, as well as temporal sequencing of multimodality treatment; and discuss future directions in combined therapy.
Latest:
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseDrs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Latest:
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseDrs. Kato and Kurzrock discuss the potential reasons why some cancer patients experience hyperprogression of disease while on immunotherapy treatment.
Latest:
Highlights of USPSTF Updates to Prostate Cancer Screening GuidelinesUSPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Latest:
Quiz: The Role of CAR T Cells in Multiple MyelomaHow much do you know about the role of CAR T cells in multiple myeloma? Here's your chance to find out.
Latest:
How Does Pre-emptive Plerixafor Affect Stem Cell Mobilization for Myeloma Transplant?A new study suggests there is a cost and efficiency benefit to pre-emptively administrating plerixafor during stem cell collection.
Latest:
Updates on Genetic Testing in Breast CancerIn this video, Dr. Allison Kurian discusses polygenic risk scores, genetic testing in diverse populations, and more as they relate to breast cancer.
Latest:
Managing Adverse Effects in Patients with HER2+ Breast CancerHarold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.
Latest:
A 79-Year-Old Man on Nivolumab with Itchy Erythematous PatchesA 79-year-old white man presented with an ulcerated chest wall lesion developing from an existing mole.
Latest:
E. David Crawford, MD, Reviews Unmet Needs Addressed by FDA Approval of Darolutamide, Docetaxel, and ADT in mHSPCIn an interview with CancerNetwork®, E. David Crawford, MD, discussed implications from the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer based on findings from the phase 3 ARASENS trial.
Latest:
CAR T-Cell Therapy in ALL: Formidible Challenges RemainAt the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
Latest:
Treatment Options Expanding in Renal CarcinomaFirst- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando.
Latest:
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial CancerAn 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy.
Latest:
Eileen Parkes on Why Cancer Researchers Are Excited About STING AgonistsONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy.
Latest:
The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer PatientsThis article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.
Latest:
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesHere we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
Latest:
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesHere we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
Latest:
Everolimus Plus Letrozole Effective in Endometrial CarcinomaFindings from the GOG-3007 study suggest everolimus plus letrozole might be effective in advanced persistent or recurrent endometrial carcinoma.
Latest:
Updates to the US Preventive Services Task Force Guideline on Ovarian Cancer ScreeningIn this interview, Dr. Stephanie Blank discusses the recently released updates to the US Preventive Services Task Force Guideline on Ovarian Cancer Screening, and how patients and clinicians should interpret them and take action.
Latest:
45-Year-Old Female With Gross Hematuria Post Partial NephrectomyA 45-year-old female presents with gross hematuria 5 days after a laparoscopic partial nephrectomy for renal cell cancer. What is your diagnosis?
Latest:
Evaluating Two RT-Plus-Chemotherapy Strategies in Bladder Cancer Patients Undergoing Bladder SurgeryIn this interview, we spoke with John J. Coen, MD, a radiation oncologist who presented results at the 2018 Genitourinary Cancers Symposium of a phase II study exploring two different radiation-plus-chemotherapy combination strategies in patients undergoing bladder surgery for their tumors.
Latest:
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast CancerTucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
